Vaxart Inc Total Liabilities
Vaxart Inc total liabilities. Based on the latest financial reports, Vaxart Inc (VXRT) has total liabilities worth $85.94 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Vaxart Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Vaxart Inc (1985–2025)
Total liabilities of Vaxart Inc from 1985 to 2025. This chart illustrates how Vaxart Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Vaxart Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Vaxart Inc Competitors by Total Liabilities
The table below lists competitors of Vaxart Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cyprium Metals Ltd
AU:CYM
|
Australia | AU$105.51 Million |
|
Dhampur Sugar Mills Limited
NSE:DHAMPURSUG
|
India | Rs12.17 Billion |
|
Decisive Dividend Corp
V:DE
|
Canada | CA$145.14 Million |
|
Kt Skylife
KO:053210
|
Korea | ₩415.51 Billion |
|
Petrochemical
TA:PTCH
|
Israel | ILA641.07 Million |
|
RiverNorth Managed Duration Municipal Income Fund II Inc.
NYSE:RMMZ
|
USA | $95.41 Million |
|
Besiktas Futbol Yatirimlari Sanayi ve Ticaret AS
IS:BJKAS
|
Turkey | TL23.00 Billion |
|
Shanghai Diesel Engine Co Ltd B
SHG:900920
|
China | $5.06 Billion |
Liability Composition Analysis (1985–2025)
This chart breaks down Vaxart Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Vaxart Inc.
Liquidity & Leverage Metrics
Vaxart Inc Total Liabilities Ratios Explained
Vaxart Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.91 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.48 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vaxart Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vaxart Inc (1985–2025)
The table below shows the annual total liabilities of Vaxart Inc from 1985 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $98.28 Million | -8.55% |
| 2024-12-31 | $107.46 Million | +215.84% |
| 2023-12-31 | $34.02 Million | -21.33% |
| 2022-12-31 | $43.25 Million | +28.58% |
| 2021-12-31 | $33.64 Million | +15.28% |
| 2020-12-31 | $29.18 Million | +21.17% |
| 2019-12-31 | $24.08 Million | +0.38% |
| 2018-12-31 | $23.99 Million | +12.10% |
| 2017-12-31 | $21.40 Million | -19.25% |
| 2016-12-31 | $26.50 Million | +167.68% |
| 2015-12-31 | $9.90 Million | -63.47% |
| 2014-12-31 | $27.10 Million | +52.25% |
| 2013-12-31 | $17.80 Million | +10.56% |
| 2012-12-31 | $16.10 Million | -58.82% |
| 2011-12-31 | $39.09 Million | -26.65% |
| 2010-12-31 | $53.30 Million | +57.18% |
| 2009-12-31 | $33.91 Million | +48.47% |
| 2008-12-31 | $22.84 Million | -75.19% |
| 2007-12-31 | $92.04 Million | -40.42% |
| 2006-12-31 | $154.49 Million | -7.77% |
| 2005-12-31 | $167.51 Million | +99.77% |
| 2004-12-31 | $83.85 Million | +23.34% |
| 2003-12-31 | $67.98 Million | +55.26% |
| 2002-12-31 | $43.79 Million | -64.43% |
| 2001-12-31 | $123.10 Million | -16.31% |
| 2000-12-31 | $147.09 Million | -5.95% |
| 1999-12-31 | $156.40 Million | -4.69% |
| 1998-12-31 | $164.10 Million | +9.25% |
| 1997-12-31 | $150.20 Million | +29.48% |
| 1996-12-31 | $116.00 Million | +69.10% |
| 1995-12-31 | $68.60 Million | +63.33% |
| 1994-12-31 | $42.00 Million | +20.34% |
| 1993-12-31 | $34.90 Million | +3.87% |
| 1992-12-31 | $33.60 Million | +192.17% |
| 1991-12-31 | $11.50 Million | -0.86% |
| 1990-12-31 | $11.60 Million | -21.09% |
| 1989-12-31 | $14.70 Million | +16.67% |
| 1988-12-31 | $12.60 Million | +125.00% |
| 1987-12-31 | $5.60 Million | -23.29% |
| 1986-12-31 | $7.30 Million | 0.00% |
| 1985-12-31 | $7.30 Million | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more